Hand, Foot and Mouth Disease
Conditions
Keywords
HFMD, EV71, Enterovirus, INV21, Encephalitis
Brief summary
The purpose of this study is to evaluate the safety and immune response of an inactivated vaccine to prevent hand, foot and mouth disease (HFMD) caused by Enterovirus 71 (EV71).
Detailed description
Hand, foot and mouth disease (HFMD) caused by Enterovirus 71 (EV71) can be severely debilitating for some children with a risk of paralysis and death. The most susceptible age group is the 1 to 5 year olds, and the disease is spread via the oral-fecal route. Currently, there is no antiviral therapy nor there is a vaccine available to prevent HFMD. In this study, an inactivated vaccine (INV21) based on the EV71 antigen will be evaluated in terms of safety and immune response that is generated after two doses of the vaccine are given to healthy adults. Safety assessments include the frequency and severity of systemic adverse events as well as local reactions. Immune response will be assessed by measurement of EV71 neutralizing antibody levels at specified time points throughout the study.
Interventions
BIOLOGICALINV21 Low Dose
Inactivated EV71 vaccine containing whole viral particles of EV71 formulated with aluminum hydroxide.
BIOLOGICALINV21 High Dose
Inactivated EV71 vaccine consisting of whole viral particles of EV71 formulated with aluminum hydroxide.
BIOLOGICALPlacebo
Phosphate Buffered Saline (PBS)
Sponsors
Inviragen Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
21 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Male or female aged 21 to 45 years, inclusive, at time of screening * In good health as determined by medical history and physical examination. * Normal clinical safety laboratory examinations. * Body mass index (BMI) in the range 19-28 kg/m2. * Documented negative serology for HIV, Hepatitis C antibody, and Hepatitis B surface antigen. * Females of child bearing potential must have a negative urine pregnancy test result during screening and a negative urine pregnancy test immediately prior to vaccination. * Willing and able to give written informed consent to participate. * Willing and able to communicate with the Investigator and understand the requirements of the study. * Low levels of EV71 neutralizing antibody.
Exclusion criteria
* Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent * Clinically significant hematological (including bleeding disorders), renal, hepatic, pulmonary (including asthma), central nervous system (including epilepsy, seizures, convulsions, or chronic migraines), cardiovascular, or gastrointestinal disorders, according to Investigator's judgment. * Ongoing rash or other dermatologic disease. * Abnormal ECG as assessed by the Investigator. * History of diabetes mellitus. * Hypersensitivity to any vaccine. * History of severe HFMD with CNS involvement. * Receipt of any vaccine in the 4 weeks preceding the first trial vaccination. * Planned receipt of any vaccine in the 4 weeks following each of the vaccinations in this study. * History of thymic pathology, thymectomy, myasthenia or any immunodeficiency. * History of recurring migraines or on prescription medication for treatment of recurring headaches or migraines. * Positive urine test for drugs of abuse. * Females who are pregnant or lactating
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of systemic adverse events and local reactions in healthy adults following two doses of INV21 given 28 days apart | 56 days | Frequency and severity of systemic adverse events up to 56 days post first dose. Frequency and severity of local reactions up to 14 days post each dose. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Immunogenicity of INV21 vaccine in healthy adults following two doses given 28 days apart | 8 months | Geometric mean titers based on neutralizing antibody titers. Measurement of fold-increase over baseline of neutralizing titers against EV71. Durability of immune response at 2 months and 6 months after the last dose. |
Countries
Singapore
Outcome results
None listed